company background image
AKBL.F logo

ALK-Abelló OTCPK:AKBL.F Stock Report

Last Price

US$18.50

Market Cap

US$4.2b

7D

0%

1Y

n/a

Updated

19 Mar, 2024

Data

Company Financials +

AKBL.F Stock Overview

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.

AKBL.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

ALK-Abelló A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ALK-Abelló
Historical stock prices
Current Share Pricekr.18.50
52 Week Highkr.19.90
52 Week Lowkr.8.20
Beta0.44
1 Month Change6.87%
3 Month Change39.62%
1 Year Changen/a
3 Year Change-95.23%
5 Year Change-88.75%
Change since IPO-83.18%

Recent News & Updates

Recent updates

Shareholder Returns

AKBL.FUS PharmaceuticalsUS Market
7D0%-0.3%0.5%
1Yn/a22.4%29.0%

Return vs Industry: Insufficient data to determine how AKBL.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AKBL.F performed against the US Market.

Price Volatility

Is AKBL.F's price volatile compared to industry and market?
AKBL.F volatility
AKBL.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: AKBL.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine AKBL.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,824Peter Hallinghttps://www.alk.net

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

ALK-Abelló A/S Fundamentals Summary

How do ALK-Abelló's earnings and revenue compare to its market cap?
AKBL.F fundamental statistics
Market capUS$4.17b
Earnings (TTM)US$70.84m
Revenue (TTM)US$703.17m

58.8x

P/E Ratio

5.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AKBL.F income statement (TTM)
Revenuekr.4.82b
Cost of Revenuekr.1.79b
Gross Profitkr.3.04b
Other Expenseskr.2.55b
Earningskr.486.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 03, 2024

Earnings per share (EPS)2.20
Gross Margin62.94%
Net Profit Margin10.07%
Debt/Equity Ratio10.4%

How did AKBL.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.